entertainment -WSS

entertainment

author：Wikipedia 2025-10-04 11:35:27 - browse：81758

The New York Stock Exchange (NYSE) — Spencer Platt/Getty Images

Biohaven Pharmaceuticals said Wednesday that a new type of experimental medicine reduced levels of a disease-causing immune molecule by up to 37% in an early-stage study of human volunteers — a result that the company called “positive” as a proof of concept but that also fell short of investor expectations.

The drug, called BHV-1300, belongs to a new class of antibody medicines that shuttle harmful proteins to the liver so they can be removed from the body. BHV-1300 is specifically designed to reduce levels of an autoantibody called IgG that is implicated in rheumatoid arthritis, myasthenia gravis, and other autoimmune disorders.

In its Phase 1 study, Biohaven tested four escalating doses of BHV-1300 in healthy volunteers, showing a reduction in levels of IgG of 5%, 15%, 30%, and 37%, respectively, the company said. The reductions in IgG levels, which occurred relatively quickly in just four to five days, did not cause significant, adverse changes in liver enzyme levels, Biohaven added — an important safety check given the mechanism of the drug.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： How CO2 helps viruses stay alive longer in the air

explore

WSS

Vaccine advisory panel ACIP left half staffed by HHS

Vaccine advisory panel ACIP left half staffed by HHS

FTC loses bid to block Novant's North Carolina hospital merger

Structure Therapeutics oral GLP

Private equity deals in Medicare Advantage declines

For pregnant people, addiction treatment shouldn't mean a call to child protective services

Wikipedia

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

United colonoscopy coverage change 'may cost lives,' doctors say

Congress needs to close a vaccine

United colonoscopy coverage change 'may cost lives,' doctors say

ASCO Takeaways: Winners, snoozers, and the art of cancer care

The high cost of giving birth even with insurance

FTC loses bid to block Novant's North Carolina hospital merger

Heart attack and stroke risk calculators need revising

Congress needs to close a vaccine

New air purifier tech could be key to improving indoor air quality

BioAge raises $170M for combination therapy with Zepbound

leisure time

FDA approves Moderna’s RSV vaccine, its second licensed product

'Revelatory' study finds a smoking impact that remains after quitting

Structure Therapeutics oral GLP

Fight over Supreme Court dialysis ruling puts kidney patients at risk

An outdated Medicare rule harms dementia patients with anxiety

Sutter Health’s antitrust win overturned by appeals court

explore

explore

hotspot

explore